|
FR104F
(https=)
|
1960-11-05 |
|
|
|
|
US3117160A
(en)
|
1961-07-27 |
1964-01-07 |
Pfizer & Co C |
Aralkylamines
|
|
US3198834A
(en)
|
1964-07-27 |
1965-08-03 |
Snc Science Union Et Compagnie |
Optical isomers of trifluoromethylated phenethylamines
|
|
GB1254332A
(en)
|
1969-02-27 |
1971-11-17 |
Science Union & Cie |
Amino acids and their derivatives and processes for preparing them
|
|
DE2143204C3
(de)
|
1971-08-28 |
1979-09-27 |
Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt |
N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
|
|
DE2150399A1
(de)
|
1971-10-09 |
1973-04-12 |
Hoechst Ag |
Neue oxime
|
|
GB1413078A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
|
|
GB1413070A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of - norfenfluramine and - fenfluramine and salts thereof
|
|
US4452815A
(en)
|
1980-06-16 |
1984-06-05 |
Massachusetts Institute Of Technology |
Method of utilizing d,l-fenfluramine for modifying feeding behavior
|
|
US4309445A
(en)
|
1980-06-16 |
1982-01-05 |
Massachusetts Institute Of Technology |
d-Fenfluramine for modifying feeding behavior
|
|
DE3717434C1
(de)
|
1987-05-23 |
1988-09-15 |
Degussa |
Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
|
|
KR890003368A
(ko)
|
1987-08-06 |
1989-04-14 |
원본미기재 |
특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
|
|
US4857553A
(en)
|
1987-08-06 |
1989-08-15 |
A. H. Robins Company, Incorporated |
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
|
|
HU204497B
(en)
|
1989-10-09 |
1992-01-28 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenfluramine
|
|
IT1238686B
(it)
|
1990-02-09 |
1993-09-01 |
Lab Mag Spa |
Procedimento per la preparazione di levo e destro fenfluramina
|
|
FR2684552B1
(fr)
|
1991-12-06 |
1995-04-28 |
Adir |
Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
|
|
US5985880A
(en)
|
1996-06-05 |
1999-11-16 |
Delta Pharmaceuticals |
Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
|
|
US5708018A
(en)
|
1993-08-06 |
1998-01-13 |
Pharmacia & Upjohn Company |
2-aminoindans as selective dopamine D3 ligands
|
|
US5834477A
(en)
|
1993-12-08 |
1998-11-10 |
The United States Of America As Represented By The Secretary Of The Army |
Opiate analgesic formulation with improved safety
|
|
US5412102A
(en)
|
1994-05-27 |
1995-05-02 |
Syntex (U.S.A.) Inc. |
Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
|
|
DE69520430T2
(de)
|
1994-06-03 |
2001-10-18 |
The Jmde Trust, Newton |
Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
|
|
IT1298349B1
(it)
|
1996-05-29 |
2000-01-05 |
Alfa Chem Ital |
Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
|
|
IT1292885B1
(it)
|
1997-04-28 |
1999-02-11 |
Alfa Chem Ital |
Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
|
|
EP0920864A1
(en)
|
1997-12-03 |
1999-06-09 |
Pfizer Products Inc. |
Combination therapy including a specific beta-3 agonist and an anorectic agent
|
|
US20020098175A1
(en)
|
1998-06-16 |
2002-07-25 |
Zohoungbogbo Mathias C. |
Dietetic food composition and dietetic method using such composition
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
DK1140061T3
(da)
|
1998-12-23 |
2003-08-25 |
Orphan Medical Inc |
Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US7124031B1
(en)
|
2000-05-11 |
2006-10-17 |
Medco Health Solutions, Inc. |
System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
|
|
US20020032581A1
(en)
|
2000-07-17 |
2002-03-14 |
Reitberg Donald P. |
Single-patient drug trials used with accumulated database: risk of habituation
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
CA2446904A1
(en)
|
2001-05-24 |
2003-04-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of drug esters through an inhalation route
|
|
ES2339339T3
(es)
|
2001-06-22 |
2010-05-19 |
Universite Catholique De Louvain |
Perlas o capsulas de hidrogel como medios artificiales para la oviposicion de insectos y la cria de endoparasitoides.
|
|
NZ530889A
(en)
|
2001-07-31 |
2005-03-24 |
Wyeth Corp |
Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
|
|
AUPR732601A0
(en)
|
2001-08-28 |
2001-09-20 |
Polychip Pharmaceuticals Pty Ltd |
Methods for the synthesis of amines such as ephedrine and inter mediates
|
|
KR100989647B1
(ko)
|
2001-09-24 |
2010-10-26 |
오레곤 헬스 앤드 사이언스 유니버시티 |
식습관의 변화
|
|
RU2317104C2
(ru)
|
2001-09-24 |
2008-02-20 |
Импиэриэл Инноувейшнс Лимитид |
Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
|
|
US6599901B1
(en)
|
2001-11-19 |
2003-07-29 |
Hoffman-La Roche Inc. |
Pyridone substituted benzothiazole derivatives
|
|
US7101572B2
(en)
*
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
|
WO2003082191A2
(en)
|
2002-03-28 |
2003-10-09 |
Merck & Co., Inc. |
Substituted 2,3-diphenyl pyridines
|
|
US7668730B2
(en)
|
2002-12-17 |
2010-02-23 |
JPI Commercial, LLC. |
Sensitive drug distribution system and method
|
|
WO2005004865A1
(en)
|
2003-07-08 |
2005-01-20 |
Georg-August-Universität Göttingen |
Use of 5-ht4(a)-serotonin receptor agonists
|
|
GB0410266D0
(en)
|
2004-05-07 |
2004-06-09 |
Ketocytonyx Inc |
Treatment of apoptosis
|
|
US9820658B2
(en)
|
2006-06-30 |
2017-11-21 |
Bao Q. Tran |
Systems and methods for providing interoperability among healthcare devices
|
|
EP1863381A4
(en)
|
2005-03-21 |
2009-09-09 |
Health Smart Ltd |
SYSTEM FOR CONTINUOUS BLOOD PRESSURE MONITORING
|
|
RU2007148444A
(ru)
|
2005-05-25 |
2009-06-27 |
Янссен Фармацевтика Н.В. (Be) |
Педиатрическая композиция топирамата
|
|
US20100088778A1
(en)
|
2005-06-16 |
2010-04-08 |
John Charles Mulley |
Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
|
|
GB0515090D0
(en)
|
2005-07-22 |
2005-08-31 |
Birmingham Res & Dev Ltd |
Novel epilepsy treatment
|
|
US9125900B2
(en)
|
2005-09-14 |
2015-09-08 |
University Of The Witwatersrand, Johannesburg |
Pharmaceutical composition
|
|
EP3703058A1
(en)
|
2005-11-29 |
2020-09-02 |
Children's Hospital Medical Center |
A method of selecting a medication for a patient
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
AU2007213069B2
(en)
|
2006-02-06 |
2010-12-23 |
Novartis Ag |
Combination of organic compounds
|
|
DE102006030113B4
(de)
|
2006-06-28 |
2009-02-12 |
Chemische Fabrik Budenheim Kg |
Graphitfreier Hochtemperatur-Schmierstoff
|
|
CN101600436A
(zh)
|
2006-08-31 |
2009-12-09 |
艾伯塔大学校董 |
使用正变构ampa受体调节剂抑制呼吸抑制的方法
|
|
EP2115648A2
(en)
|
2007-01-31 |
2009-11-11 |
Quintiles Transnational Corp., Inc. |
Methods and systems for site startup
|
|
WO2008104524A1
(en)
|
2007-02-28 |
2008-09-04 |
Smithkline Beecham Corporation |
Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
ES2620672T3
(es)
|
2008-01-09 |
2017-06-29 |
Charleston Laboratories, Inc. |
Comprimidos de doble capa que comprenden oxicodona y prometazina
|
|
EP2331088A4
(en)
|
2008-08-06 |
2011-10-12 |
Gosforth Ct Holdings Pty Ltd |
COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
|
|
WO2010020585A1
(en)
|
2008-08-18 |
2010-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin reuptake inhibitors for the treatment of rett syndrome
|
|
SI2735338T1
(sl)
|
2008-09-05 |
2019-04-30 |
Grunenthal Gmbh |
Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina
|
|
US8386274B1
(en)
|
2008-09-17 |
2013-02-26 |
Mckesson Financial Holdings Limited |
Systems and methods for a prescription safety network utilizing eligibility verification transactions
|
|
KR20110067103A
(ko)
*
|
2008-10-09 |
2011-06-21 |
아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 |
파라세타몰을 포함하는 액체 약학적 제제
|
|
WO2010042780A2
(en)
|
2008-10-10 |
2010-04-15 |
The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research |
Methods and compositions for treating status epilepticus and seizures causing status epilepticus
|
|
TWI503101B
(zh)
|
2008-12-15 |
2015-10-11 |
波提亞斯數位康健公司 |
與身體有關的接收器及其方法
|
|
WO2010104841A2
(en)
|
2009-03-09 |
2010-09-16 |
Celgene Corporation |
Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
|
|
JP5711724B2
(ja)
|
2009-04-15 |
2015-05-07 |
リサーチ・トライアングル・インスティチュート |
モノアミン再取り込み阻害剤
|
|
WO2010124137A1
(en)
|
2009-04-22 |
2010-10-28 |
Millennium Pharmacy Systems, Inc. |
Pharmacy management and administration with bedside real-time medical event data collection
|
|
US9453027B2
(en)
|
2009-07-27 |
2016-09-27 |
Daljit Singh Dhanoa |
Deuterium-enriched pyridinonecarboxamides and derivatives
|
|
WO2011085181A1
(en)
|
2010-01-08 |
2011-07-14 |
Eurand, Inc. |
Taste masked topiramate composition and an orally disintegrating tablet comprising the same
|
|
AU2011224520B2
(en)
|
2010-03-09 |
2016-04-21 |
Perceptimed, Inc. |
Medication verification and dispensing
|
|
WO2011119227A2
(en)
|
2010-03-25 |
2011-09-29 |
Columbia Northwest Pharmaceuticals, Llc |
Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
|
|
JP2011221623A
(ja)
|
2010-04-06 |
2011-11-04 |
Kakimori Suri |
在宅診療支援システム及び方法
|
|
AU2011255276B2
(en)
|
2010-05-21 |
2016-09-22 |
Research Triangle Institute |
Phenylmorpholines and analogues thereof
|
|
EP2399513B1
(en)
|
2010-06-23 |
2017-01-04 |
Qatar University Qstp-B |
System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
|
|
WO2012015712A1
(en)
|
2010-07-30 |
2012-02-02 |
Schering Corporation |
Inhibition of cyp3a drug metabolism
|
|
EP3485878A1
(en)
|
2010-09-01 |
2019-05-22 |
Arena Pharmaceuticals, Inc. |
Modified-release dosage forms of 5-ht2c agonists useful for weight management
|
|
US20120270848A1
(en)
|
2010-10-22 |
2012-10-25 |
Galleon Pharmaceuticals, Inc. |
Novel Compositions and Therapeutic Methods Using Same
|
|
RU2541159C2
(ru)
|
2010-10-26 |
2015-02-10 |
АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи |
Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
|
|
RU103209U1
(ru)
|
2010-10-29 |
2011-03-27 |
Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" |
Клиническая информационная система
|
|
GB2487712B
(en)
|
2011-01-04 |
2015-10-28 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
|
|
JP5693325B2
(ja)
|
2011-03-29 |
2015-04-01 |
小林クリエイト株式会社 |
健診結果出力システム及び健診結果出力プログラム
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
WO2013096878A1
(en)
|
2011-12-22 |
2013-06-27 |
University Of Idaho |
Garcinia buchananii baker compounds, compositions and related methods
|
|
US9346798B2
(en)
|
2012-02-13 |
2016-05-24 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
US20130218586A1
(en)
|
2012-02-21 |
2013-08-22 |
Frederic J. Huser |
Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
|
|
JP6075973B2
(ja)
|
2012-06-04 |
2017-02-08 |
富士通株式会社 |
健康状態判定装置およびその作動方法
|
|
CA2891342A1
(en)
|
2012-11-15 |
2014-05-22 |
Galleon Pharmaceuticals, Inc. |
Novel orally bioavailable breathing control modulating compounds, and methods of using same
|
|
WO2014106825A2
(en)
|
2013-01-06 |
2014-07-10 |
Jonathan Rabinowitz |
Methods and devices for identifying improper medical reporting
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
DK3035926T3
(da)
|
2013-08-19 |
2020-08-31 |
Univ California |
Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
US20150141415A1
(en)
|
2013-11-20 |
2015-05-21 |
Omonike Arike Olaleye |
Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
|
|
CN103886415A
(zh)
|
2014-03-25 |
2014-06-25 |
北京蝶禾谊安信息技术有限公司 |
药品管理方法和装置
|
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
KR102245345B1
(ko)
|
2014-09-29 |
2021-04-28 |
조게닉스 인터내셔널 리미티드 |
의약품 배포 제어를 위한 제어 시스템
|
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
EP4059522A1
(en)
|
2015-02-06 |
2022-09-21 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
|
CN113546174A
(zh)
|
2015-02-25 |
2021-10-26 |
加利福尼亚大学董事会 |
用于治疗病症的5ht激动剂
|
|
US10292996B2
(en)
|
2015-03-26 |
2019-05-21 |
The Trustees Of Columbia University In The City Of New York |
Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
|
|
JP6599484B2
(ja)
|
2015-06-17 |
2019-10-30 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法
|
|
WO2017003822A1
(en)
|
2015-06-30 |
2017-01-05 |
Galleon Pharmaceuticals, Inc. |
Novel breathing control modulating compounds, and methods of making and using same
|
|
ES2925951T3
(es)
|
2015-07-22 |
2022-10-20 |
John Hsu |
Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
|
|
HUE066912T2
(hu)
|
2015-08-24 |
2024-09-28 |
Zogenix International Ltd |
Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával
|
|
US20170071949A1
(en)
|
2015-09-14 |
2017-03-16 |
Zogenix International Limited |
Combination treatment of specific forms of epilepsy
|
|
EP3170807B1
(en)
|
2015-11-23 |
2019-12-11 |
Frau Pharma S.r.l. |
New method for synthesis of fenfluramine
|
|
PT4293009T
(pt)
|
2015-12-22 |
2025-09-08 |
Zogenix International Ltd |
Composições de fenfluramina e métodos de preparação das mesmas
|
|
WO2017112701A1
(en)
|
2015-12-22 |
2017-06-29 |
Zogenix International Limited |
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
JP6753418B2
(ja)
|
2016-01-14 |
2020-09-09 |
Ａｇｃ株式会社 |
フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
|
|
AU2017315273B2
(en)
|
2016-08-24 |
2021-04-29 |
Zogenix International Limited |
Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
|
|
US20180092864A1
(en)
|
2016-09-30 |
2018-04-05 |
Zogenix International Limited |
Compositions and methods for treating seizure disorders
|
|
CA3062247A1
(en)
|
2017-05-09 |
2018-11-15 |
Zogenix International Limited |
Methods of treating doose syndrome using fenfluramine
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
US20190091179A1
(en)
|
2017-09-26 |
2019-03-28 |
Zogenix International Limited |
Congnitive function with fenfluramine
|
|
WO2019067413A1
(en)
|
2017-09-26 |
2019-04-04 |
Zogenix International Limited |
USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
|
|
KR20210009317A
(ko)
|
2018-04-18 |
2021-01-26 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법
|
|
EP3790537A1
(en)
|
2018-05-11 |
2021-03-17 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
EP3806835A1
(en)
|
2018-06-14 |
2021-04-21 |
Zogenix International Limited |
Compositions and methods for treating respiratory depression with fenfluramine
|
|
EP3820459A1
(en)
|
2018-07-10 |
2021-05-19 |
Zogenix International Limited |
Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
|
|
AU2019384963B2
(en)
|
2018-11-19 |
2022-05-26 |
Zogenix International Limited |
Methods of treating Rett syndrome using fenfluramine
|
|
US20210401776A1
(en)
|
2018-11-30 |
2021-12-30 |
Zogenix International Limited |
Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
|
|
EP3930841A4
(en)
|
2019-02-25 |
2022-11-30 |
Zogenix International Limited |
FORMULATION TO IMPROVE SEIZURE CONTROL
|
|
US20210299064A1
(en)
|
2020-02-05 |
2021-09-30 |
Zogenix International Limited |
Method of treating patients with lennox-gastaut syndrome
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
US20220096514A1
(en)
|
2020-09-29 |
2022-03-31 |
Zogenix International Limited |
Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
|